Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.31 |
| ▸ | S100A4 | P26447 | 1/20 | 0.31 |
| ▸ | CDC25B | P30305 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.30 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.30 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.30 |
| ▸ | ITGAL | P20701 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31020837 | 1.00 | CA1 (0.34) | CA1CA9CA12CA2HPGD | |
| SCHEMBL12273598 | 0.79 | — | — | |
| SCHEMBL8832624 | 0.78 | EPHX2 (0.32) | — | |
| SCHEMBL219296 | 0.72 | CA1 (0.37) | CA1CA9 | |
| SCHEMBL1404692 | 0.72 | CA1 (0.46) | CA1CA9CA12CA2CYP2B6 | |
| SCHEMBL29412512 | 0.72 | CA12 (0.32) | CA1CA9CA12CA2 | |
| SCHEMBL27652109 | 0.71 | CYP2B6 (0.34) | CA1CA9CA12CA2HPGD | |
| SCHEMBL218596 | 0.68 | CA1 (0.36) | CA1CA9 | |
| SCHEMBL218355 | 0.68 | CA1 (0.32) | CA1CA9 | |
| SCHEMBL2317954 | 0.68 | LTA4H (0.38) | CA1CA9CA12CA2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1076 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120051457-A | Oxalic acid amide compound, pharmaceutical composition containing oxalic acid amide compound, preparation method and application of oxalic acid amide compound | 四川科伦博泰生物医药股份有限公司 | 2025-05-27 | — | — | CN | claimed |
| CN-114341127-B | Aminopyrazine compounds as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2024-12-17 | — | — | CN | claimed |
| WO-2024104244-A1 | OXAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2024-05-23 | — | — | WO | claimed |
| US-20240100123-A1 | NOVEL AIMP1 PROTEIN FRAGMENT AND HAIR GROWTH-PROMOTING COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | CUREBIO THERAPEUTICS (KR) | 2024-03-28 | — | — | US | claimed |
| US-11872263-B2 | AIMP1 protein fragment and hair growth-promoting composition containing same as active ingredient | CUREBIO THERAPEUTICS (KR) | 2024-01-16 | — | — | US | claimed |
| WO-2023217201-A2 | NOVEL PYRIMIDO-HETEROCYCLIC NOVEL COMPOUND SERVING AS WEE1 INHIBITOR AND APPLICATION THEREOF | 杭州德睿智药科技有限公司 | 2023-11-16 | — | — | WO | claimed |
| US-20220289712-A1 | AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | BEONE MEDICINES I GMBH (CH) | 2022-09-15 | — | — | US | claimed |
| CN-109715655-B | Novel fragment of AIMP1 protein and composition for promoting hair growth comprising the same | CUREBIO疗法株式会社 | 2022-07-22 | — | — | CN | claimed |
| CN-114341127-A | Aminopyrazine compounds as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2022-04-12 | — | — | CN | claimed |
| US-20210244793-A1 | NOVEL AIMP1 PROTEIN FRAGMENT AND HAIR GROWTH-PROMOTING COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | CUREBIO THERAPEUTICS (KR) | 2021-08-12 | — | — | US | claimed |
| WO-1995013815-A1 | COMBINATION METHOD FOR THE TREATMENT OF PATTERNED ALOPECIA | MERCK & CO., INC. (US) | 1995-05-26 | — | — | WO | claimed |
| WO-1994015602-A1 | COMBINATION METHOD FOR TREATING PATTERNED ALOPECIA WITH 17β-N-SUBSTITUTED-CARBAMOYL-4-AZA-5α-ANDROST-1-EN-3-ONES AND MINOXIDIL | MERCK & CO., INC. (US) | 1994-07-21 | — | — | WO | claimed |
| EP-0542802-A1 | STIMULATION OF HAIR GROWTH WITH POTASSIUM CHANNEL OPENERS AND 5-g(a)-REDUCTASE INHIBITORS. | UPJOHN CO (US) | 1993-05-26 | — | — | EP | claimed |
| WO-1992009259-A1 | STIMULATION OF HAIR GROWTH WITH POTASSIUM CHANNEL OPENERS AND AN ANDROGEN RECEPTOR BLOCKER | THE UPJOHN COMPANY (US) | 1992-06-11 | — | — | WO | claimed |
| WO-1992002225-A1 | STIMULATION OF HAIR GROWTH WITH POTASSIUM CHANNEL OPENERS AND 5α-REDUCTASE INHIBITORS | THE UPJOHN COMPANY (US) | 1992-02-20 | — | — | WO | claimed |
| EP-0465583-A1 | USE OF A POTASSIC AGONIST IN THE TREATMENT OF GLAUCOMA | ELF SANOFI (FR) | 1992-01-15 | — | — | EP | claimed |
| US-5071871-A | Pharmaceutically useful benzo(β)pyranes and pyranopyridines | SANDOZ LTD. (CH) | 1991-12-10 | — | — | US | claimed |
| WO-1990011758-A2 | USE OF A POTASSIC AGONIST IN THE TREATMENT OF GLAUCOMA | SANOFI (FR) | 1990-10-18 | — | — | WO | claimed |
| US-4812459-A | PYRANOPYRIDINES | BEECHAM GROUP P.L.C. (GB) | 1989-03-14 | — | — | US | claimed |
| EP-0227932-A1 | Novel fused pyridine compounds, intermediates for the preparation of, and use of said compounds as herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1987-07-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289712-A1 | AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | MAPKAPK5, STK25, STK35 | CA1 4519/4885CA9 4290/4885CA12 4597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.